Showing results (31-40 of 483) with videos related to
Sort By:
Pageof 49
Wiener Klinische Wochenschrift|November 4, 1988
[Defects in the prostaglandin system. VI. Acquired plasma factor defect]H Sinzinger, P Fitscha, F Rauscha, et al.British Journal of Clinical Pharmacology|March 1, 1992
Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in manH Sinzinger, F Rauscha, J O'Grady, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 15, 1999
Isradipine lowers human arterial low density lipoprotein retention in vivoH Kritz, H Sinzinger, P Fitscha, et al.Blood Pressure. Supplement|January 1, 1994
Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wallC Pirich, P Fitscha, P Schmid, et al.Basic Research in Cardiology|November 1, 1988
Beneficial effect of PGI2 on circulating endothelial cellsH Sinzinger, F Rauscha, P Fitscha, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|November 1, 1988
Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?H Sinzinger, J Kaliman, P Fitscha, et al.American Journal of Hematology|February 1, 1990
Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigationH Sinzinger, F Rauscha, P Fitscha, et al.Wiener Klinische Wochenschrift|September 13, 1985
[Accelerated degradation of prostacyclin in diabetic plasma--a further factor in the impairment of hemostatic balance?]H Sinzinger, J Kaliman, P Fitscha, et al.European Journal of Clinical Pharmacology|January 1, 1992
Isradipine improves platelet function in hypertensivesH Sinzinger, I Virgolini, F Rauscha, et al.Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|March 1, 1994
Isradipine inhibits mitotic and proliferative activity in the arterial wallP Fitscha, F Rauscha, J O'Grady, et al.Pageof 49